RxDoctor Payments DataLook up a doctor →

Ahmed Khan, MD

Pulmonary Disease · Schenectady, NYNPI 1881870178

Payments from drug & device makers

$453,465in general payments, 2019–2025

Across 436 payments — averaging $1040.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$216K
  • AstraZeneca$138K
  • Mylan Specialty L.p.$59K
  • GSK$21K
  • Pulmonx Corporation$8K
  • Intuitive Surgical$4K
  • plus $7K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi US Services Inc.57$215,877
AstraZeneca53$138,190
Mylan Specialty L.p.7$58,978
GSK118$21,054
Pulmonx Corporation12$8,470
Intuitive Surgical10$4,039
Johnson & Johnson(2 entities)19$1,471
Eli Lilly1$951
Medical Device Business Services, Inc.8$936
Boehringer Ingelheim17$359
AbbVie17$353
Novartis14$316
Harmony Biosciences LLC11$267
Regeneron Healthcare Solutions, Inc.7$208
Amgen(2 entities)9$192
Philips North America LLC9$172
Genentech USA, Inc.9$156
Pfizer7$156
Sanofi5$125
Inspire Medical Systems, Inc.1$119
Verona Pharma, Inc.4$113
Si-bone, Inc.1$112
Electromed, Inc.6$111
Galvanize Therapeutics, Inc1$107
Merck4$80
Chiesi USA, Inc.3$75
Grifols USA, LLC3$68
Insmed, Inc.3$59
Astellas Pharma US Inc2$46
Jazz Pharmaceuticals Inc.2$45
Shionogi Inc2$42
United Therapeutics Corporation2$40
E.r. Squibb & Sons, L.L.C.2$39
Baxter Healthcare1$27
Takeda Pharmaceuticals U.S.A., Inc.1$23
Vapotherm Inc1$14
Veran Medical Technologies, Inc.1$14
Sunovion Pharmaceuticals Inc.1$14
Teva Pharmaceuticals USA, Inc.1$12
Portola Pharmaceuticals, LLC1$12
Shockwave Medical, Inc1$12
Gilead1$11
Coaptech, Inc.1$0

How this compares

$453,465 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York →

Medicare billing

Part B allowed, 2024
$114,536
Medicare patients
282
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Schenectady

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →